PDCD1 and hepatocellular carcinoma: Immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD1)/programmed cell death ligand-1 (PDL1) pathway constituted the backbone of systemic therapy for patients with un-resectable hepatocellular carcinoma (HCC) [1].